
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 18, 2019

Tyme Technologies, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-38169
(Commission
File Number)

45-3864597
(IRS Employer
Identification No.)

17 State Street – 7th Floor
New York, New York 10004
(Address of principal executive offices, including zip code)

(212) 461-2315
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Introductory Comment – Use of Terminology

Throughout this Current Report on Form 8-K, the terms “the Company,” “we” and “our” refer to Tyme Technologies, Inc., a Delaware corporation, together with its subsidiaries (“Tyme”).

Item 7.01 Regulation FD Disclosure.

At 10:43 a.m. Eastern time, January 18, 2019, Tyme Technologies, Inc. replaced on its website the poster entitled “Phase II Trial of SM-88 in Patients with Metastatic Pancreatic Cancer: Preliminary Results of the 1st Stage” to replace the Figure 2 presented therein, which had been included in error, with an updated Figure 2.

- The original version of the poster included four patients who were not evaluable, per protocol, because these were not 2-month scans
- Figure 2 reflected in the poster now represents the best response for evaluable patients

The updated poster is available on the Company’s website (www.tymeinc.com/data-publications).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Tyme Technologies, Inc.

Dated: January 18, 2019

By: /s/ Ben R. Taylor

Ben R. Taylor, President and Chief Financial Officer